Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of NNC6019-0001 at two dose levels in transthyretin amyloid cardiomyopathy
2023-506824-96-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in 6-minute walk test (6MWT) distance and Change in NT-proBNP. Started Oct 2023; status: completed.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2023-506824-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506824-96-00.